auto‑immune diseases

Ermium Therapeutics is a series A biotechnology company developing innovative therapies for auto-immune diseases.

Founded on a breakthrough discovery

We develop innovative therapies for auto-immune diseases, based on a breakthrough discovery demonstrating that CXCR4 is a master regulator of inflammation.

type I interferon-driven Auto Immune Diseases

Ermium first in class therapeutics address type I interferon-driven diseases including Systemic lupus erythematosus, Dermatomyositis, Sjögren’s syndrome, Monogenic interferonopathies.

Working Together

Ermium Therapeutics was founded in June 2019 by Jean-Philippe HERBEUVAL, Kurma Partners, Domain Therapeutics and Erganeo. Since, we haven’t ceased to welcome new partners.